2020 Q4 Form 10-K Financial Statement
#000156459021017097 Filed on March 31, 2021
Income Statement
| Concept | 2020 Q4 | 2020 | 2019 Q4 |
|---|---|---|---|
| Revenue | $18.51M | $27.46M | $1.784M |
| YoY Change | 937.71% | 396.58% | 107.53% |
| Cost Of Revenue | $10.01M | $21.34M | $2.870M |
| YoY Change | 248.78% | 94.35% | 17.85% |
| Gross Profit | $8.500M | $6.120M | -$1.090M |
| YoY Change | -879.82% | -212.29% | -30.83% |
| Gross Profit Margin | 45.92% | 22.29% | -61.11% |
| Selling, General & Admin | $5.300M | $16.37M | $3.400M |
| YoY Change | 55.88% | 26.8% | 10.62% |
| % of Gross Profit | 62.35% | 267.48% | |
| Research & Development | $1.230M | $5.200M | $1.160M |
| YoY Change | 6.03% | 10.64% | -10.0% |
| % of Gross Profit | 14.47% | 84.97% | |
| Depreciation & Amortization | $250.0K | $1.090M | $240.0K |
| YoY Change | 4.17% | 17.2% | 9.09% |
| % of Gross Profit | 2.94% | 17.81% | |
| Operating Expenses | $6.530M | $5.200M | $4.560M |
| YoY Change | 43.2% | -70.47% | 4.53% |
| Operating Profit | $1.970M | -$15.47M | -$5.650M |
| YoY Change | -134.87% | -32.92% | -4.85% |
| Interest Expense | -$60.00K | -$240.0K | -$60.00K |
| YoY Change | 0.0% | -196.01% | -25.0% |
| % of Operating Profit | -3.05% | ||
| Other Income/Expense, Net | $0.00 | -$2.100M | $0.00 |
| YoY Change | 14.75% | -100.0% | |
| Pretax Income | $1.900M | -$17.81M | -$5.710M |
| YoY Change | -133.27% | -29.16% | -4.99% |
| Income Tax | $0.00 | $0.00 | |
| % Of Pretax Income | |||
| Net Earnings | $1.900M | -$17.80M | -$5.710M |
| YoY Change | -133.27% | -29.08% | -5.06% |
| Net Earnings / Revenue | 10.26% | -64.82% | -320.11% |
| Basic Earnings Per Share | -$0.20 | ||
| Diluted Earnings Per Share | $257.5K | -$1.503M | -$0.20 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 29.13M | ||
| Diluted Shares Outstanding | 29.13M |
Balance Sheet
| Concept | 2020 Q4 | 2020 | 2019 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $14.37M | $14.37M | $9.300M |
| YoY Change | 54.52% | 54.52% | 171.93% |
| Cash & Equivalents | $14.37M | $9.301M | |
| Short-Term Investments | |||
| Other Short-Term Assets | $2.150M | $2.150M | $300.0K |
| YoY Change | 616.67% | 616.67% | -30.23% |
| Inventory | $1.930M | $1.930M | $768.0K |
| Prepaid Expenses | |||
| Receivables | $14.15M | $14.14M | $3.527M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $32.60M | $32.59M | $13.89M |
| YoY Change | 134.62% | 134.63% | 131.12% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $2.318M | $14.43M | $1.504M |
| YoY Change | 54.09% | 275.78% | -45.09% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $426.0K | $430.0K | |
| YoY Change | |||
| Total Long-Term Assets | $14.86M | $14.86M | $3.840M |
| YoY Change | 286.92% | 286.98% | 40.18% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $32.60M | $32.59M | $13.89M |
| Total Long-Term Assets | $14.86M | $14.86M | $3.840M |
| Total Assets | $47.45M | $47.45M | $17.73M |
| YoY Change | 167.6% | 167.63% | 102.65% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $8.366M | $8.360M | $2.012M |
| YoY Change | 315.84% | 315.92% | -1.37% |
| Accrued Expenses | $3.166M | $3.170M | $1.980M |
| YoY Change | 59.88% | 12.41% | 2.69% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $960.0K | $960.0K | $720.0K |
| YoY Change | 33.33% | 33.33% | 12.5% |
| Total Short-Term Liabilities | $12.50M | $12.49M | $5.559M |
| YoY Change | 124.8% | 124.64% | 20.59% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $1.460M | $1.460M | $970.0K |
| YoY Change | 50.52% | 50.52% | -2.02% |
| Other Long-Term Liabilities | $9.810M | $9.810M | $0.00 |
| YoY Change | -100.0% | ||
| Total Long-Term Liabilities | $11.27M | $11.27M | $970.0K |
| YoY Change | 1061.86% | 1061.86% | -11.67% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $12.50M | $12.49M | $5.559M |
| Total Long-Term Liabilities | $11.27M | $11.27M | $970.0K |
| Total Liabilities | $23.76M | $23.76M | $6.532M |
| YoY Change | 263.76% | 263.86% | 14.44% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$263.5M | -$245.7M | |
| YoY Change | 7.25% | 11.46% | |
| Common Stock | $287.2M | $256.9M | |
| YoY Change | 11.79% | 14.95% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $23.69M | $23.69M | $11.20M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $47.45M | $47.45M | $17.73M |
| YoY Change | 167.6% | 167.63% | 102.65% |
Cashflow Statement
| Concept | 2020 Q4 | 2020 | 2019 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | $1.900M | -$17.80M | -$5.710M |
| YoY Change | -133.27% | -29.08% | -5.06% |
| Depreciation, Depletion And Amortization | $250.0K | $1.090M | $240.0K |
| YoY Change | 4.17% | 17.2% | 9.09% |
| Cash From Operating Activities | -$1.110M | -$19.80M | -$5.470M |
| YoY Change | -79.71% | -14.1% | 0.92% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$810.0K | $867.0K | -$440.0K |
| YoY Change | 84.09% | 17.91% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | -$810.0K | -$867.0K | -$440.0K |
| YoY Change | 84.09% | 17.91% | |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -580.0K | 25.72M | 8.670M |
| YoY Change | -106.69% | -13.29% | -7981.82% |
| NET CHANGE | |||
| Cash From Operating Activities | -1.110M | -19.80M | -5.470M |
| Cash From Investing Activities | -810.0K | -867.0K | -440.0K |
| Cash From Financing Activities | -580.0K | 25.72M | 8.670M |
| Net Change In Cash | -2.500M | 5.067M | 2.760M |
| YoY Change | -190.58% | -13.8% | -149.91% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$1.110M | -$19.80M | -$5.470M |
| Capital Expenditures | -$810.0K | $867.0K | -$440.0K |
| Free Cash Flow | -$300.0K | -$20.67M | -$5.030M |
| YoY Change | -94.04% | -13.11% | -7.2% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q4 | us-gaap |
Cash
Cash
|
14367942 | |
| CY2020Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
14144911 | |
| CY2020Q4 | us-gaap |
Inventory Net
InventoryNet
|
1929624 | |
| CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2151527 | |
| CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
32594004 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2317616 | |
| CY2019Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
729330 | |
| CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
9776349 | |
| CY2019Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
1606387 | |
| CY2020Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
2337709 | |
| CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
425908 | |
| CY2019Q4 | us-gaap |
Assets
Assets
|
17732644 | |
| CY2020Q4 | us-gaap |
Assets
Assets
|
47451586 | |
| CY2019Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2011827 | |
| CY2019Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020 | dei |
City Area Code
CityAreaCode
|
858 | |
| CY2020 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
| CY2020 | dei |
Local Phone Number
LocalPhoneNumber
|
320-8200 | |
| CY2020 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | |
| CY2020 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
92121 | |
| CY2020 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
| CY2020 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
80-0943522 | |
| CY2020 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
9955 Mesa Rim Road | |
| CY2020 | dei |
Security12b Title
Security12bTitle
|
Common Stock, par value $.0001 per share | |
| CY2020 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
San Diego | |
| CY2019 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
5940843 | |
| CY2019 | us-gaap |
Interest Expense
InterestExpense
|
249984 | |
| CY2020 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2020 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2020 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2020 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2020 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
false | |
| CY2020 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
8364858 | |
| CY2019Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1980204 | |
| CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
3165669 | |
| CY2020 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2020 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
| CY2020 | dei |
Entity File Number
EntityFileNumber
|
001-36284 | |
| CY2019Q4 | us-gaap |
Cash
Cash
|
9301406 | |
| CY2019Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
3527078 | |
| CY2019Q4 | us-gaap |
Inventory Net
InventoryNet
|
767986 | |
| CY2019Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
296127 | |
| CY2019Q4 | us-gaap |
Assets Current
AssetsCurrent
|
13892597 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1504330 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
842452 | |
| CY2019Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
724329 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
963726 | |
| CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
12494253 | |
| CY2020 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
42929653 | |
| CY2019 | bioc |
Warrant Inducement Expense
WarrantInducementExpense
|
1831116 | |
| CY2020 | bioc |
Warrant Inducement Expense
WarrantInducementExpense
|
2102109 | |
| CY2019 | bioc |
Deemed Dividend Related To Warrants Down Round Provision
DeemedDividendRelatedToWarrantsDownRoundProvision
|
121572 | |
| CY2020 | bioc |
Deemed Dividend Related To Warrants Down Round Provision
DeemedDividendRelatedToWarrantsDownRoundProvision
|
2774 | |
| CY2019 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-25259611 | |
| CY2020 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-17809678 | |
| CY2019 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-12.23 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3042519 | |
| CY2019 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
869579 | |
| CY2019 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
4850470 | |
| CY2019 | bioc |
Adjustment To Additional Paid In Capital Warrant Inducement Expense
AdjustmentToAdditionalPaidInCapitalWarrantInducementExpense
|
1831116 | |
| CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
940984 | |
| CY2020 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
2401704 | |
| CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
42430 | |
| CY2020 | bioc |
Adjustment To Additional Paid In Capital Warrant Inducement Expense
AdjustmentToAdditionalPaidInCapitalWarrantInducementExpense
|
2102109 | |
| CY2019 | us-gaap |
Profit Loss
ProfitLoss
|
-25138039 | |
| CY2020 | us-gaap |
Profit Loss
ProfitLoss
|
-17806904 | |
| CY2019 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
931655 | |
| CY2020 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1085234 | |
| CY2019 | bioc |
Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
|
-158341 | |
| CY2020 | bioc |
Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
|
-84110 | |
| CY2019 | bioc |
Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
|
-14167 | |
| CY2020 | bioc |
Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
|
-244825 | |
| CY2019 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
869579 | |
| CY2019 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
1831116 | |
| CY2020 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
2102109 | |
| CY2020 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
1680 | |
| CY2020 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
10617833 | |
| CY2020 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1406464 | |
| CY2020 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-533460 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-23049261 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-19787100 | |
| CY2019 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
735300 | |
| CY2020 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
866814 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-735300 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-866814 | |
| CY2019 | bioc |
Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
|
25744997 | |
| CY2020 | bioc |
Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
|
24193928 | |
| CY2019 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
2513173 | |
| CY2020 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
2401704 | |
| CY2019 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
2337298 | |
| CY2020 | bioc |
Proceeds From Exercise Of Overallotment Warrants
ProceedsFromExerciseOfOverallotmentWarrants
|
659958 | |
| CY2019 | us-gaap |
Interest Paid Net
InterestPaidNet
|
249984 | |
| CY2019 | bioc |
Financial Guarantee Insurance Contracts Premium Payable
FinancialGuaranteeInsuranceContractsPremiumPayable
|
393000 | |
| CY2019 | us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
632000 | |
| CY2020 | bioc |
Landlord Receivable For Accrued Leasehold Improvement Costs
LandlordReceivableForAccruedLeaseholdImprovementCosts
|
1631000 | |
| CY2019Q1 | bioc |
Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
|
6800000 | |
| CY2018Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
12.00 | |
| CY2019Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
4.05 | |
| CY2018Q1 | bioc |
Deemed Dividend Related To Warrants Down Round Provision
DeemedDividendRelatedToWarrantsDownRoundProvision
|
122000 | |
| CY2019Q1 | bioc |
Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
|
7600000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
595000 | |
| CY2019Q1 | us-gaap |
Share Price
SharePrice
|
13.70 | |
| CY2019Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
|
1 | |
| CY2019Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
12.50 | |
| CY2019Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
192500 | |
| CY2019Q4 | bioc |
Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
|
6400000 | |
| CY2019Q4 | bioc |
Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital
OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital
|
998000 | |
| CY2020 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. The Company and Business Activities </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was founded in California in May 1997 and <font style="color:#000000;">is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or liquid biopsy. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays, performed on blood, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease when compared with tissue biopsy and radiographic imaging. Additionally, commencing in October 2017, the Company’s pathology partnership program, branded as Empower TC</font><font style="color:#000000;font-size:7.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> TM</sup></font><font style="color:#000000;">, provides the unique ability for pathologists to participate in the interpretation of liquid biopsy results and is available to pathology practices and hospital systems throughout the United States. Further, sales to laboratory supply distributors of the Company’s proprietary blood collection tubes commenced in June 2018, which allow for the intact transport of liquid biopsy samples for research use only, or RUO, from regions around the world.</font></p> <p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic continues to evolve, and the extent to which COVID-19 may impact the Company’s business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. While the Company experienced increased revenue levels in 2020 related to its COVID-19 testing business and has attained net income for the first time in its operating history in the fourth quarter in 2020, these results are not expected to be indicative of future results as the COVID-19 pandemic subsides.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"> </p> | |
| CY2020 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates these estimates and judgments, including those related to accounts receivable reserves, inventory reserves, long-lived assets, income taxes, including uncertain tax benefits, estimated transaction price for revenues, stock-based compensation, incremental borrowing rate estimates, and the determination of the Company’s ability to continue as a going concern. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. Though the impact of the COVID-19 pandemic on the Company’s business and operating results presents additional uncertainty, the Company continues to use the best information available to determine its significant accounting estimates.</p> | |
| CY2020 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of a large number of geographically dispersed clients diversified across various customer types.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the years ended December 31, 2019 and 2020 were as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:66.44%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.32%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage/CARES Act</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, as of December 31, 2019 and 2020 were as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:67.34%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.96%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.96%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.08%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.7%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.96%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage/CARES Act</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.7%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.96%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.7%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.96%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.7%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one reportable business segment and historically has derived most revenues only from within the United States.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain components used in the Company’s current or planned products are currently sourced from one supplier, for which alternative suppliers exist but the Company has not validated the product(s) of such alternative supplier(s), and substitutes for these components may not be obtained easily or may require substantial design or manufacturing modifications. </p> | |
| CY2020Q4 | bioc |
Aggregate Net Interest Bearing Indebtedness
AggregateNetInterestBearingIndebtedness
|
2400000 | |
| CY2020Q4 | bioc |
Other Non Interest Bearing Current Liabilities
OtherNonInterestBearingCurrentLiabilities
|
3200000 | |
| CY2020Q4 | bioc |
Aggregate Net Interest Bearing Indebtedness Due Within One Year
AggregateNetInterestBearingIndebtednessDueWithinOneYear
|
964000 | |
| CY2020Q3 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.10 | |
| CY2020Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
| CY2020Q3 | us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
On September 3, 2020, pursuant to the approval of the Company’s board of directors, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock using a ratio of one-for-ten. | |
| CY2018Q4 | bioc |
Gross And Net Accounts Receivable
GrossAndNetAccountsReceivable
|
1574325 | |
| CY2019 | bioc |
Gross And Net Accounts Receivable For Amounts Recognized Upon Delivery
GrossAndNetAccountsReceivableForAmountsRecognizedUponDelivery
|
5528566 | |
| CY2019 | bioc |
Gross And Net Accounts Receivable For Settlements Upon Adjudication
GrossAndNetAccountsReceivableForSettlementsUponAdjudication
|
-3575813 | |
| CY2019Q4 | bioc |
Gross And Net Accounts Receivable
GrossAndNetAccountsReceivable
|
3527078 | |
| CY2020 | bioc |
Gross And Net Accounts Receivable For Amounts Recognized Upon Delivery
GrossAndNetAccountsReceivableForAmountsRecognizedUponDelivery
|
27461398 | |
| CY2020 | bioc |
Gross And Net Accounts Receivable For Settlements Upon Adjudication
GrossAndNetAccountsReceivableForSettlementsUponAdjudication
|
-16843565 | |
| CY2019Q4 | us-gaap |
Unbilled Receivables Current
UnbilledReceivablesCurrent
|
29000 | |
| CY2020Q4 | us-gaap |
Unbilled Receivables Current
UnbilledReceivablesCurrent
|
4500000 | |
| CY2020 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | |
| CY2020 | us-gaap |
Concentration Risk Supplier
ConcentrationRiskSupplier
|
one supplier | |
| CY2019 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | |
| CY2020 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | |
| CY2019Q4 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
|
0 | |
| CY2020Q4 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
|
0 | |
| CY2019 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | |
| CY2020 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
99000 | |
| CY2019Q1 | us-gaap |
Share Price
SharePrice
|
22.50 | |
| CY2019Q1 | bioc |
Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
|
2000000 | |
| CY2019Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
12.00 | |
| CY2020Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
1900000 | |
| CY2020Q1 | bioc |
Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
|
8600000 | |
| CY2020Q1 | bioc |
Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
|
6100000 | |
| CY2020Q2 | bioc |
Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
|
9600000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
2300000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
1600000 | |
| CY2020Q2 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
2230000 | |
| CY2020Q1 | us-gaap |
Share Price
SharePrice
|
4.00 | |
| CY2020Q1 | us-gaap |
Share Price
SharePrice
|
4.10 | |
| CY2020Q2 | us-gaap |
Share Price
SharePrice
|
4.60 | |
| CY2019Q1 | bioc |
Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
|
9.50 | |
| CY2019Q1 | bioc |
Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
|
10.10 | |
| CY2019Q2 | bioc |
Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
|
1800000 | |
| CY2019Q4 | bioc |
Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
|
2.40 | |
| CY2020Q1 | bioc |
Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
|
1900000 | |
| CY2019Q1 | bioc |
Adjusted Exercise Price Of Warrants
AdjustedExercisePriceOfWarrants
|
12.00 | |
| CY2019Q1 | bioc |
Adjusted Exercise Price Of Warrants
AdjustedExercisePriceOfWarrants
|
12.50 | |
| CY2020Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
3.495 | |
| CY2019Q1 | bioc |
Estimated Fair Value Of Warrants
EstimatedFairValueOfWarrants
|
2.70 | |
| CY2019Q1 | bioc |
Estimated Fair Value Of Warrants
EstimatedFairValueOfWarrants
|
2.70 | |
| CY2019Q1 | bioc |
Estimated Fair Value Of Warrants Increased
EstimatedFairValueOfWarrantsIncreased
|
2.90 | |
| CY2019Q1 | bioc |
Estimated Fair Value Of Warrants Increased
EstimatedFairValueOfWarrantsIncreased
|
3.00 | |
| CY2019Q1 | bioc |
Class Of Warrants Or Rights Eligible For Price Modification
ClassOfWarrantsOrRightsEligibleForPriceModification
|
216725 | |
| CY2019Q1 | bioc |
Class Of Warrants Or Rights Eligible For Price Modification
ClassOfWarrantsOrRightsEligibleForPriceModification
|
476000 | |
| CY2019Q1 | bioc |
Warrant Inducement Expense
WarrantInducementExpense
|
60000 | |
| CY2019Q1 | bioc |
Warrant Inducement Expense
WarrantInducementExpense
|
130000 | |
| CY2019Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
630548 | |
| CY2020Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
1235620 | |
| CY2019Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
130898 | |
| CY2020Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
691126 | |
| CY2019Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
6540 | |
| CY2020Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
2878 | |
| CY2019Q4 | us-gaap |
Inventory Gross
InventoryGross
|
767986 | |
| CY2020Q4 | us-gaap |
Inventory Gross
InventoryGross
|
1929624 | |
| CY2019Q4 | us-gaap |
Machinery And Equipment Gross
MachineryAndEquipmentGross
|
2857538 | |
| CY2020Q4 | us-gaap |
Machinery And Equipment Gross
MachineryAndEquipmentGross
|
2974320 | |
| CY2019Q4 | us-gaap |
Furniture And Fixtures Gross
FurnitureAndFixturesGross
|
156987 | |
| CY2020Q4 | us-gaap |
Furniture And Fixtures Gross
FurnitureAndFixturesGross
|
156987 | |
| CY2019Q4 | bioc |
Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
|
1552891 | |
| CY2020Q4 | bioc |
Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
|
2428211 | |
| CY2019Q4 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
570173 | |
| CY2020Q4 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
570173 | |
| CY2019Q4 | us-gaap |
Construction In Progress Gross
ConstructionInProgressGross
|
625038 | |
| CY2020Q4 | us-gaap |
Construction In Progress Gross
ConstructionInProgressGross
|
761221 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
5762627 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
6890912 | |
| CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
4258297 | |
| CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
4573296 | |
| CY2019Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
298855 | |
| CY2020Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
452118 | |
| CY2019Q4 | us-gaap |
Accrued Vacation Current
AccruedVacationCurrent
|
622792 | |
| CY2020Q4 | us-gaap |
Accrued Vacation Current
AccruedVacationCurrent
|
868557 | |
| CY2019Q4 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
748742 | |
| CY2020Q4 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
1022421 | |
| CY2019Q4 | us-gaap |
Accrued Sales Commission Current
AccruedSalesCommissionCurrent
|
89562 | |
| CY2020Q4 | us-gaap |
Accrued Sales Commission Current
AccruedSalesCommissionCurrent
|
456526 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
220253 | |
| CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
366047 | |
| CY2020 | us-gaap |
Lease Practical Expedients Package
LeasePracticalExpedientsPackage
|
true | |
| CY2019Q1 | bioc |
Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
|
149000 | |
| CY2019Q1 | bioc |
Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
|
monthly | |
| CY2019Q1 | bioc |
Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
|
36 | |
| CY2019Q1 | bioc |
Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
|
5013 | |
| CY2019Q1 | bioc |
Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
|
180000 | |
| CY2019Q1 | bioc |
Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
|
2022-02 | |
| CY2019Q3 | bioc |
Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
|
100000 | |
| CY2019Q3 | bioc |
Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
|
monthly | |
| CY2019Q3 | bioc |
Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
|
48 | |
| CY2019Q3 | bioc |
Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
|
2023-05 | |
| CY2019Q3 | bioc |
Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
|
245000 | |
| CY2019Q3 | bioc |
Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
|
monthly | |
| CY2019Q3 | bioc |
Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
|
36 | |
| CY2019Q3 | bioc |
Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
|
8253 | |
| CY2019Q3 | bioc |
Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
|
297000 | |
| CY2019Q3 | bioc |
Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
|
2022-08 | |
| CY2019Q3 | bioc |
Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
|
89000 | |
| CY2019Q3 | bioc |
Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
|
monthly | |
| CY2019Q3 | bioc |
Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
|
60 | |
| CY2019Q3 | bioc |
Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
|
1770 | |
| CY2019Q3 | bioc |
Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
|
106000 | |
| CY2019Q3 | bioc |
Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
|
2024-09 | |
| CY2020Q1 | bioc |
Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
|
197000 | |
| CY2020Q1 | bioc |
Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
|
11000 | |
| CY2020Q1 | bioc |
Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
|
monthly | |
| CY2020Q1 | bioc |
Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
|
4532 | |
| CY2020Q1 | bioc |
Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
|
288 | |
| CY2020Q1 | bioc |
Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
|
265000 | |
| CY2020Q1 | bioc |
Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
|
14000 | |
| CY2020Q1 | bioc |
Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
|
2025-01 | |
| CY2020Q1 | bioc |
Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
|
2024-02 | |
| CY2020Q2 | bioc |
Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
|
161000 | |
| CY2020Q2 | bioc |
Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
|
monthly | |
| CY2020Q2 | bioc |
Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
|
60 | |
| CY2020Q2 | bioc |
Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
|
3337 | |
| CY2020Q2 | bioc |
Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
|
185000 | |
| CY2020Q2 | bioc |
Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
|
2025-03 | |
| CY2020Q2 | bioc |
Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
|
334000 | |
| CY2020Q2 | bioc |
Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
|
monthly | |
| CY2020Q2 | bioc |
Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
|
8966 | |
| CY2020Q2 | bioc |
Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
|
469000 | |
| CY2020Q2 | bioc |
Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
|
2025-06 | |
| CY2020Q3 | bioc |
Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
|
143000 | |
| CY2020Q3 | bioc |
Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
|
monthly | |
| CY2020Q3 | bioc |
Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
|
60 | |
| CY2020Q3 | bioc |
Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
|
2772 | |
| CY2020Q3 | bioc |
Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
|
166000 | |
| CY2020Q3 | bioc |
Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
|
2025-07 | |
| CY2020Q3 | bioc |
Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
|
226000 | |
| CY2020Q3 | bioc |
Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
|
monthly | |
| CY2020Q3 | bioc |
Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
|
16427 | |
| CY2020Q3 | bioc |
Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
|
261000 | |
| CY2020Q3 | bioc |
Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
|
2025-07 | |
| CY2020Q4 | bioc |
Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
|
192000 | |
| CY2020Q4 | bioc |
Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
|
monthly | |
| CY2020 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
227517 | |
| CY2019 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1272024 | |
| CY2020 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1411958 | |
| CY2020Q4 | bioc |
Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
|
48 | |
| CY2020Q4 | bioc |
Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
|
5382 | |
| CY2020Q4 | bioc |
Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
|
258000 | |
| CY2020Q4 | bioc |
Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
|
2024-10 | |
| CY2020Q4 | bioc |
Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
|
73000 | |
| CY2020Q4 | bioc |
Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
|
91000 | |
| CY2020Q4 | bioc |
Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
|
monthly | |
| CY2020Q4 | bioc |
Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
|
monthly | |
| CY2020Q4 | bioc |
Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
|
60 | |
| CY2020Q4 | bioc |
Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
|
36 | |
| CY2020Q4 | bioc |
Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
|
1394 | |
| CY2020Q4 | bioc |
Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
|
3002 | |
| CY2020Q4 | bioc |
Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
|
84000 | |
| CY2020Q4 | bioc |
Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
|
108000 | |
| CY2020Q4 | bioc |
Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
|
2025-11 | |
| CY2020Q4 | bioc |
Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
|
2023-12 | |
| CY2019Q4 | bioc |
Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
|
2335717 | |
| CY2020Q4 | bioc |
Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
|
12114058 | |
| CY2019Q4 | bioc |
Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
|
1566781 | |
| CY2020Q4 | bioc |
Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
|
963726 | |
| CY2019Q4 | bioc |
Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
|
973189 | |
| CY2020Q4 | bioc |
Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
|
11264911 | |
| CY2019 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
470486 | |
| CY2020 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
694249 | |
| CY2019 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
249984 | |
| CY2019 | bioc |
Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
|
1992494 | |
| CY2020 | bioc |
Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
|
2333724 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
|
1026710 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
765006 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
626131 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
341425 | |
| CY2020Q4 | bioc |
Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
|
88402 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
2847674 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
424398 | |
| CY2020Q4 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
2423276 | |
| CY2020Q4 | bioc |
Finance Leases Maintenance And Sales Tax Obligation Payments Due Next Twelve Months
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueNextTwelveMonths
|
104011 | |
| CY2020Q4 | bioc |
Finance Leases Maintenance And Sales Tax Obligation Payments Due In Two Years
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInTwoYears
|
81741 | |
| CY2020Q4 | bioc |
Finance Leases Maintenance And Sales Tax Obligation Payments Due In Three Years
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInThreeYears
|
66230 | |
| CY2020Q4 | bioc |
Finance Leases Maintenance And Sales Tax Obligation Payments Due In Four Years
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInFourYears
|
46281 | |
| CY2020Q4 | bioc |
Finance Leases Maintenance And Sales Tax Obligation Payments Due Thereafter
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueThereafter
|
6809 | |
| CY2020Q4 | bioc |
Finance Leases Maintenance And Sales Tax Obligation Payments Due
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDue
|
305072 | |
| CY2020Q4 | bioc |
Finance Leases Maintenance And Sales Tax Obligation Payments Net
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsNet
|
305072 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
788446 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1586210 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
1629025 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
1671841 | |
| CY2020Q4 | bioc |
Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
|
11995433 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
17670955 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
7865594 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
9805361 | |
| CY2019 | us-gaap |
Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
|
249984 | |
| CY2020 | us-gaap |
Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
|
227517 | |
| CY2019 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1430366 | |
| CY2020 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1511907 | |
| CY2020Q4 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y2M12D | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P10Y5M1D | |
| CY2020Q4 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.163 | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.120 | |
| CY2020 | bioc |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Equity Incentive Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEquityIncentivePlans
|
2 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.0000 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.0000 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
19560 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
267899 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
14041 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
273418 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
858523 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
53237 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1078704 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
1059534 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
414.10 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
9.10 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
37.00 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
36.14 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
4.51 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
22.26 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
11.64 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
11.76 | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P9Y2M12D | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P9Y3M | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P9Y4M9D | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P9Y4M6D | |
| CY2020 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y8M26D | |
| CY2020Q4 | bioc |
Common Stock Warrants Outstanding Intrinsic Value
CommonStockWarrantsOutstandingIntrinsicValue
|
243000 | |
| CY2019Q4 | bioc |
Common Stock Warrants Outstanding Intrinsic Value
CommonStockWarrantsOutstandingIntrinsicValue
|
0 | |
| CY2019 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3069017 | |
| CY2020 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2122582 | |
| CY2020Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-4878334 | |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-19711749 | ||
| CY2020Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
13333427 | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
11324289 | ||
| CY2020Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
13333427 | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
11324289 | ||
| CY2020Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.37 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.74 | ||
| CY2020Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.37 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.74 | ||
| CY2020 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
250000 | |
| CY2019 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
228000 | |
| CY2019 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-5278232 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-3738797 | |
| CY2019 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-764997 | |
| CY2020 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-939936 | |
| CY2019 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
|
103617 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
|
100728 | |
| CY2019 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
174128 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
|
1824076 | |
| CY2019Q4 | bioc |
Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
|
205542 | |
| CY2020Q4 | bioc |
Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
|
2394201 | |
| CY2019Q4 | bioc |
Deferred Tax Assets Fixed Assets
DeferredTaxAssetsFixedAssets
|
460218 | |
| CY2020Q4 | bioc |
Deferred Tax Assets Fixed Assets
DeferredTaxAssetsFixedAssets
|
659656 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
|
829801 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
|
860310 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
21179084 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
28099764 | |
| CY2019Q4 | bioc |
Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
|
569870 | |
| CY2020Q4 | bioc |
Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
|
2957921 | |
| CY2019Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
569870 | |
| CY2020Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
2957921 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
94489 | |
| CY2019 | bioc |
Income Tax Reconciliation Warrant Inducement Expense
IncomeTaxReconciliationWarrantInducementExpense
|
384534 | |
| CY2020 | bioc |
Income Tax Reconciliation Warrant Inducement Expense
IncomeTaxReconciliationWarrantInducementExpense
|
441443 | |
| CY2019 | bioc |
Income Tax Reconciliation Expiration Of Net Operating Losses
IncomeTaxReconciliationExpirationOfNetOperatingLosses
|
35487 | |
| CY2020 | bioc |
Income Tax Reconciliation Expiration Of Net Operating Losses
IncomeTaxReconciliationExpirationOfNetOperatingLosses
|
912357 | |
| CY2019 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
359765 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
370350 | |
| CY2019 | us-gaap |
Income Tax Reconciliation Tax Contingencies State And Local
IncomeTaxReconciliationTaxContingenciesStateAndLocal
|
388 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Tax Contingencies State And Local
IncomeTaxReconciliationTaxContingenciesStateAndLocal
|
-164229 | |
| CY2019 | bioc |
Income Tax Reconciliation Section Three Eight Two Limitation
IncomeTaxReconciliationSectionThreeEightTwoLimitation
|
325046 | |
| CY2020 | bioc |
Income Tax Reconciliation Section Three Eight Two Limitation
IncomeTaxReconciliationSectionThreeEightTwoLimitation
|
183 | |
| CY2019 | us-gaap |
Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
|
-4296 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
|
6845 | |
| CY2019 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
-83353 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
-875362 | |
| CY2019 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
5467443 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
4532629 | |
| CY2020Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
13900000 | |
| CY2020 | us-gaap |
Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
|
which will begin to expire in 2021 | |
| CY2019 | bioc |
Percent Of Uncertain Income Tax Positions Recognized
PercentOfUncertainIncomeTaxPositionsRecognized
|
0.50 | |
| CY2020 | bioc |
Percent Of Uncertain Income Tax Positions Recognized
PercentOfUncertainIncomeTaxPositionsRecognized
|
0.50 | |
| CY2019Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
| CY2020Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
13118923 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
18672696 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
3318475 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
3688825 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
|
3246125 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
20609214 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
25141843 | |
| CY2020Q4 | bioc |
Percentage Of Change In Ownership
PercentageOfChangeInOwnership
|
0.50 | |
| CY2020 | bioc |
Period Of Change In Ownership
PeriodOfChangeInOwnership
|
P3Y | |
| CY2016Q1 | us-gaap |
Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
|
1062500 | |
| CY2020 | bioc |
Unconditional Purchase Commitment Frequency Of Periodic Payment
UnconditionalPurchaseCommitmentFrequencyOfPeriodicPayment
|
Quarterly | |
| CY2020 | us-gaap |
Unrecorded Unconditional Purchase Obligation Date
UnrecordedUnconditionalPurchaseObligationDate
|
2020-05-31 | |
| CY2020Q4 | us-gaap |
Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
|
0 | |
| CY2019Q4 | us-gaap |
Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
|
91000 | |
| CY2019 | bioc |
Finance Leases Sales Tax And Maintenance Obligations Expense
FinanceLeasesSalesTaxAndMaintenanceObligationsExpense
|
122000 | |
| CY2020 | bioc |
Finance Leases Sales Tax And Maintenance Obligations Expense
FinanceLeasesSalesTaxAndMaintenanceObligationsExpense
|
129000 |
